

Mohamed Shanavas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/745475/publications.pdf>

Version: 2024-02-01

13
papers

209
citations

1651377

6
h-index

1336881

12
g-index

13
all docs

13
docs citations

13
times ranked

523
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. <i>Blood Advances</i> , 2021, 5, 2644-2649.	2.5	7
2	Intratumoral T cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. <i>Clinical and Translational Immunology</i> , 2021, 10, e1351.	1.7	1
3	Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study. <i>Blood</i> , 2021, 138, 4099-4099.	0.6	1
4	Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , 2021, 138, 882-882.	0.6	3
5	The Tumor Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma. <i>Blood</i> , 2017, 130, 728-728.	0.6	2
6	The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. <i>Blood</i> , 2017, 130, 825-825.	0.6	0
7	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 432-440.	2.0	127
8	Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e151-e156.	0.2	11
9	Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation. <i>American Journal of Hematology</i> , 2015, 90, 392-399.	2.0	17
10	Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response. <i>Leukemia and Lymphoma</i> , 2014, 55, 2398-2401.	0.6	1
11	A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 87-92.	0.2	21
12	Controversies and dilemmas in allogeneic transplantation for myelofibrosis. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 165-174.	0.7	3
13	Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1751-1757.	2.0	15